CORRECTING and REPLACING – Gemphire Therapeutics Enrolls First Patients in the ROYAL-1 Trial Investigating Gemcabene in Hypercholesterolemia
November 28, 2016 11:06 ET
|
Gemphire Therapeutics
ROYAL-1 is a Phase 2b Study to Determine Safety and Tolerability of Gemcabene in Hypercholesterolemia Not Adequately Controlled on High-Intensity or Moderate-Intensity Stable Statin TherapyTopline...
Gemphire Therapeutics Enrolls First Patients in the ROYAL-1 Trial Investigating Gemcabene in Hypercholesterolemia
November 28, 2016 06:00 ET
|
Gemphire Therapeutics
ROYAL-1 is a Phase 2b Study to Determine Safety and Tolerability of Gemcabene in Hypercholesterolemia Not Adequately Controlled on High-Intensity or Moderate-Intensity Stable Statin Therapy Topline...
Gemphire Therapeutics to Present at the Piper Jaffray Healthcare and LD Micro Main Event Conferences
November 17, 2016 16:01 ET
|
Gemphire Therapeutics
LIVONIA, Mich., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the...
Gemphire Announces Third Quarter 2016 Financial Results and Provides Corporate Update
November 02, 2016 06:00 ET
|
Gemphire Therapeutics
LIVONIA, Mich., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the...
Gemphire Therapeutics Strengthens Intellectual Property with Granting of European Patent for Gemcabene
October 31, 2016 06:00 ET
|
Gemphire Therapeutics
LIVONIA, Mich., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the...
Gemphire Therapeutics to Report Third Quarter Financial Results and Corporate Update on November 2; Corporate Presentation at the 25th Annual Credit Suisse Healthcare Conference on November 7
October 26, 2016 16:01 ET
|
Gemphire Therapeutics
LIVONIA, Mich., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the...
Gemphire Therapeutics Proudly Sponsors the FH Foundation
October 17, 2016 06:00 ET
|
Gemphire Therapeutics
LIVONIA, Mich., Oct. 17, 2016 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the...
Gemphire Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
October 07, 2016 16:30 ET
|
Gemphire Therapeutics
LIVONIA, Mich., Oct. 07, 2016 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the...
Gemphire Therapeutics Appoints Lee Golden, M.D., as Chief Medical Officer
October 06, 2016 06:00 ET
|
Gemphire Therapeutics
NORTHVILLE, Mich., Oct. 06, 2016 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (Nasdaq:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...
Gemphire Therapeutics Enrolls First Patient in the COBALT-1 Trial Investigating Gemcabene in Homozygous Familial Hypercholesterolemia
September 26, 2016 06:00 ET
|
Gemphire Therapeutics
Phase 2b Study to Determine Safety and Tolerability of Gemcabene in HoFH Topline Data Readout Currently Anticipated in First Half -2017 LIVONIA, Mich., Sept. 26, 2016 (GLOBE NEWSWIRE) --...